Extracted from this filing and checked against the source text.
M&A Transactions
SEC 8-K Item 2.01/5.01
confidence 0.9
SURGALIGN HOLDINGS, INC. completed a disposition involving Xtant Medical Holdings, Inc. for $17.0 million in cash (closed 2023-02-28).
- Action
- disposition
- Counterparty
- Xtant Medical Holdings, Inc.
- Consideration
- $17.0 million in cash
- Closing
- 2023-02-28
Exact text from the filing
the aggregate consideration paid in the Coflex Transaction for 100% of Surgalign SPV's equity securities was $17.0 million in cash
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.7
SURGALIGN HOLDINGS, INC. entered into Transition Services Agreement with Xtant Medical Holdings, Inc. (effective 2023-02-28).
- Action
- entry
- Counterparty
- Xtant Medical Holdings, Inc.
- Effective
- 2023-02-28
Exact text from the filing
Seller, Surgalign SPV and Xtant also entered into a Transition Services Agreement, dated as of February 28, 2023 (the “Transition Services Agreement”), in connection with the Coflex Transaction pursuant to which Seller has agreed to provide certain transition services to Xtant immediately after the closing for an agreed upon transition period.
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
SURGALIGN HOLDINGS, INC. entered into Equity Purchase Agreement with Xtant Medical Holdings, Inc. valued at $17.0 million (effective 2023-02-28).
- Action
- entry
- Agreement
- asset purchase
- Counterparty
- Xtant Medical Holdings, Inc.
- Value
- $17.0 million
- Effective
- 2023-02-28
Exact text from the filing
., a Delaware corporation (“Surgalign SPV”) an indirect subsidiary of Surgalign Holdings, Inc., a Delaware corporation (the “Company”), Surgalign Spine Technologies, Inc, a Delaware corporation and sole stockholder of Surgalign SPV (“Seller”), the Company and Xtant Medical Holdings, Inc., a Delaware corporation (“Xtant” or “Buyer”) entered into an Equity Purchase Agreement (the “Coflex Purchase Agreement”), pursuant to which, among other things and concurrently with execution thereof, Xtant acquired 100% of the issued and outstanding equity of Surgalign SPV, from Seller (the “Coflex Transaction”).
View on SEC.gov